Trial intelligence / Profile preview

BIA 6-512 PK Interaction with Levodopa in Healthy Volunteers

NCT03097211Phase 1Completed

Sponsor
BIAL
Start
Jul 2006
Primary completion
Oct 2006
Modality
Small Molecules
Countries
1
01

Overview

Phase 1, randomised, double-blind trial of resveratrol in Parkinson's disease (PD) (4 arms), sponsored by BIAL. Primary endpoints: Maximum observed plasma drug concentration at Day 5, Time of occurrence of Cmax at Day 5 and 3 more. Started Jul 2006; status: completed.

02

Drugs

resveratrol
03

Conditions

Parkinson's disease (PD)

Beyond the preview

Go deeper on NCT03097211.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03097211.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call